BAO PHARMA-B Surges Over 7% in Morning Trading as KJ103 Injection Advances to Priority Review

Stock News

05/13

BAO PHARMA-B (02659) rose more than 7% in morning trading. As of press time, the stock was up 6.99% to HK$29.4, with a turnover of HK$86.0639 million. On the news front, on May 12, the CDE website indicated that BAO PHARMA's KJ103 injection is proposed to be included in the priority review process. It is intended for desensitization therapy in highly sensitized kidney transplant patients, effectively clearing pre-existing HLA antibodies to prevent hyperacute rejection. According to reports, KJ103 is a first-in-class, low-immunogenicity recombinant immunoglobulin G (IgG) degrading enzyme for the treatment of various immune diseases mediated by pathological IgG antibodies. The product works by specifically cleaving and degrading pathological IgG antibodies in the bloodstream, inhibiting immune response activation, and providing a targeted, rapid new treatment option for antibody-mediated autoimmune diseases.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1182859003"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1182859003\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1182859003?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-13 10:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182859003","market":"sg","top_or_hot":-1,"title":"BAO PHARMA-B Surges Over 7% in Morning Trading as KJ103 Injection Advances to Priority Review","media":"Stock News","content":"<p>BAO PHARMA-B (02659) rose more than 7% in morning trading. As of press time, the stock was up 6.99% to HK$29.4, with a turnover of HK$86.0639 million. On the news front, on May 12, the CDE website indicated that BAO PHARMA's KJ103 injection is proposed to be included in the priority review process. It is intended for desensitization therapy in highly sensitized kidney transplant patients, effectively clearing pre-existing HLA antibodies to prevent hyperacute rejection. According to reports, KJ103 is a first-in-class, low-immunogenicity recombinant immunoglobulin G (IgG) degrading enzyme for the treatment of various immune diseases mediated by pathological IgG antibodies. The product works by specifically cleaving and degrading pathological IgG antibodies in the bloodstream, inhibiting immune response activation, and providing a targeted, rapid new treatment option for antibody-mediated autoimmune diseases.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BAO PHARMA-B Surges Over 7% in Morning Trading as KJ103 Injection Advances to Priority Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBAO PHARMA-B Surges Over 7% in Morning Trading as KJ103 Injection Advances to Priority Review\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-05-13 10:15</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>BAO PHARMA-B (02659) rose more than 7% in morning trading. As of press time, the stock was up 6.99% to HK$29.4, with a turnover of HK$86.0639 million. On the news front, on May 12, the CDE website indicated that BAO PHARMA's KJ103 injection is proposed to be included in the priority review process. It is intended for desensitization therapy in highly sensitized kidney transplant patients, effectively clearing pre-existing HLA antibodies to prevent hyperacute rejection. According to reports, KJ103 is a first-in-class, low-immunogenicity recombinant immunoglobulin G (IgG) degrading enzyme for the treatment of various immune diseases mediated by pathological IgG antibodies. The product works by specifically cleaving and degrading pathological IgG antibodies in the bloodstream, inhibiting immune response activation, and providing a targeted, rapid new treatment option for antibody-mediated autoimmune diseases.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"","article_id":"1182859003","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182859003","pubTimestamp":1778638527,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"BAO PHARMA-B (02659) rose more than 7% in morning trading. As of press time, the stock was up 6.99% to HK$29.4, with a turnover of HK$86.0639 million. On the news front, on May 12, the CDE website...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK1161":"生物科技","BK4585":"ETF&股票定投概念","02659":"宝济药业-B","VXUS":"国际股票ETF-Vanguard"},"translate_title":"宝药业-B早盘大涨超7%，KJ103注射液晋级优先审评","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1,"02659":1},"content_text":"BAO PHARMA-B (02659) rose more than 7% in morning trading. As of press time, the stock was up 6.99% to HK$29.4, with a turnover of HK$86.0639 million. On the news front, on May 12, the CDE website indicated that BAO PHARMA's KJ103 injection is proposed to be included in the priority review process. It is intended for desensitization therapy in highly sensitized kidney transplant patients, effectively clearing pre-existing HLA antibodies to prevent hyperacute rejection. According to reports, KJ103 is a first-in-class, low-immunogenicity recombinant immunoglobulin G (IgG) degrading enzyme for the treatment of various immune diseases mediated by pathological IgG antibodies. The product works by specifically cleaving and degrading pathological IgG antibodies in the bloodstream, inhibiting immune response activation, and providing a targeted, rapid new treatment option for antibody-mediated autoimmune diseases.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}